HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GED-0507

Also Known As:

(2S)-3-(4-aminophenyl)-2-methoxypropanoic acid

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - GED-0507: 2
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - GED-0507: 2

Experts

1.	Chavatte, Philippe: 2 articles (01/2021 - 12/2020)
2.	Desreumaux, Pierre: 2 articles (01/2021 - 12/2020)
3.	Dubuquoy, Caroline: 2 articles (01/2021 - 12/2020)
4.	Rousseaux, Christel: 2 articles (01/2021 - 12/2020)
5.	Spagnolo, Paolo: 2 articles (01/2021 - 12/2020)
6.	Speca, Silvia: 2 articles (01/2021 - 12/2020)

Related Diseases

1.	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/01/2021 - "In conclusion, GED-0507 demonstrated potent antifibrotic properties and might be a promising drug candidate for the treatment of pulmonary fibrosis." 01/01/2021 - "The beneficial effect of GED-0507 on pulmonary fibrosis was confirmed in vitro by its ability to control TGFβ-induced myofibroblast activation in the A549 human alveolar epithelial cell line, the MRC-5 lung fibroblast line, and primary human lung fibroblasts. " 12/01/2020 - "GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis." 01/01/2021 - "In a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, we have demonstrated that the non-racemic selective PPAR-γ modulator GED-0507 is able to reduce body weight loss, ameliorate clinical and histological features of pulmonary fibrosis, and increase survival rate without any safety concerns. "
2.	Fibrosis (Cirrhosis) 01/01/2021 - "GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro." 01/01/2021 - "We demonstrated that preventive and therapeutic administration of GED-0507 reduced the BLM-induced mRNA expression of several markers of fibrosis, including transforming growth factor (TGF)-β, alpha-smooth muscle actin, collagen and fibronectin as well as epithelial-to-mesenchymal transition (EMT) and expression of mucin 5B. "
3.	Body Weight (Weight, Body) 01/01/2021 - "In a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, we have demonstrated that the non-racemic selective PPAR-γ modulator GED-0507 is able to reduce body weight loss, ameliorate clinical and histological features of pulmonary fibrosis, and increase survival rate without any safety concerns. "

Related Drugs and Biologics

1.	Mucin-5B
2.	Peroxisome Proliferator-Activated Receptors (PPAR)
3.	Transforming Growth Factors (Transforming Growth Factor)
4.	Messenger RNA (mRNA)
5.	Fibronectins (Fibronectin)
6.	Collagen
7.	Bleomycin (Blenoxane)